MK-1242
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $10.8M | 1,163 | 36 |
| 2018 | $10.6M | 1,907 | 67 |
| 2017 | $4.6M | 1,351 | 42 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $25.5M | 3,314 | 97.7% |
| Consulting Fee | $350,300 | 110 | 1.3% |
| Travel and Lodging | $232,949 | 453 | 0.9% |
| Food and Beverage | $22,910 | 544 | 0.1% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A randomized parallel-group, placebo-controlled, double-blind, event-driven, multi-center pivotal phase III clinical outcome trial of efficacy and safety of the oral sGC stimulator Vericiguat in subjects with heart failure and reduced ejection fraction HFrEF - VerICiguaT glObal study in subjects with heart failure and Reduced ejectIon frAction VICTORIA | Merck Sharp & Dohme Corporation | $25.5M | 1 |
| A randomized parallel-group, placebo-controlled, double-blind, event-driven, multi-center pivotal phase III clinical outcome trial of efficacy and safety of the oral sGC stimulator Vericiguat in subjects with heart failure and reduced ejection fraction HFrEF - VerICiguaT glObal study in subjects with heart failure and Reduced ejectIon frAction VICTORIA | Merck Sharp & Dohme Corporation | $230.40 | 0 |
Top Doctors Receiving Payments for MK-1242
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Alexandria, LA | $25.5M | 3,307 |
| Christopher Oconnor | Cardiovascular Disease | Durham, NC | $201,820 | 103 |
| , MD, MPH | Cardiovascular Disease | Stony Brook, NY | $97,790 | 81 |
| , M.D | Cardiovascular Disease | Ponce, PR | $37,955 | 50 |
| , MD, MPH | Cardiovascular Disease | Bronx, NY | $32,443 | 47 |
| , M.D | Cardiovascular Disease | Durham, NC | $23,326 | 66 |
| , MD | Internal Medicine | Tucson, AZ | $22,408 | 38 |
| , MD | Cardiovascular Disease | Humacao, PR | $20,512 | 22 |
| , MD | Cardiovascular Disease | Brookline, MA | $15,452 | 33 |
| , MD | Internal Medicine | Mpls, MN | $12,100 | 9 |
| , M.D | Cardiovascular Disease | San Juan, PR | $10,767 | 7 |
| , M.D | Cardiovascular Disease | Durham, NC | $9,101 | 11 |
| , M.D | Cardiovascular Disease | Boston, MA | $6,650 | 2 |
| , MD | Internal Medicine | Boston, MA | $6,314 | 8 |
| , MD | Cardiovascular Disease | Winston Salem, NC | $6,001 | 4 |
| , MD | Cardiovascular Disease | Tampa, FL | $6,000 | 1 |
| , MD | Internal Medicine | Durham, NC | $5,754 | 52 |
| , M.D | Cardiovascular Disease | Baltimore, MD | $5,650 | 2 |
| , M.D | Internal Medicine | San Francisco, CA | $5,650 | 2 |
| , MD | Internal Medicine | Santurce, PR | $4,247 | 8 |
| , MD | Cardiovascular Disease | Chicago, IL | $4,000 | 1 |
| , MD | Cardiovascular Disease | Richmond, VA | $3,325 | 22 |
| , M.D | Cardiovascular Disease | Omaha, NE | $2,449 | 11 |
| , M.D | General Practice | Miami, FL | $2,153 | 16 |
| , M.D | Specialist | Columbus, GA | $2,138 | 13 |
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $26.1M
- Total Doctors 104
- Transactions 4,421
About MK-1242
MK-1242 is a drug associated with $26.1M in payments to 104 healthcare providers, recorded across 4,421 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2017 to 2019. In 2019, $10.8M was paid across 1,163 transactions to 36 doctors.
The most common payment nature for MK-1242 is "Unspecified" ($25.5M, 97.7% of total).
MK-1242 is associated with 2 research studies, including "A randomized parallel-group, placebo-controlled, double-blind, event-driven, multi-center pivotal phase III clinical outcome trial of efficacy and safety of the oral sGC stimulator Vericiguat in subjects with heart failure and reduced ejection fraction HFrEF - VerICiguaT glObal study in subjects with heart failure and Reduced ejectIon frAction VICTORIA" ($25.5M).